Skip to main content
Patent court opens door to generic versions of blockbuster MS drug

A Patent Trial and Appeal Board panel agreed with Mylan that one of Biogen's patents on Tecfidera is void, clearing the way for generic versions of the multiple sclerosis drug as soon as 2021.

Full Story: